Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-05-31
2011-05-31
Bausch, Sarae (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C436S063000
Reexamination Certificate
active
07951543
ABSTRACT:
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.
REFERENCES:
patent: 7425624 (2008-09-01), Thomae et al.
patent: 7745185 (2010-06-01), Thomae et al.
patent: 7790396 (2010-09-01), Ramsey et al.
patent: 2002/0115073 (2002-08-01), Papadopoulos et al.
patent: 2003/0170176 (2003-09-01), Leyland-Jones
patent: 2004/0072156 (2004-04-01), Nakamura et al.
patent: 2006/0177851 (2006-08-01), Brennan et al.
patent: 2006/0223065 (2006-10-01), Von Der Kammer et al.
patent: 2006/0257903 (2006-11-01), Akil et al.
patent: 2007/0031853 (2007-02-01), Stanton, Jr. et al.
patent: 2007/0105105 (2007-05-01), Clelland et al.
patent: 2007/0105128 (2007-05-01), Nakamura et al.
patent: 2009/0012371 (2009-01-01), Brennan et al.
patent: 2010/0119626 (2010-05-01), Ramsey et al.
patent: 2010/0120046 (2010-05-01), Brennan et al.
patent: 2010/0151461 (2010-06-01), Brennan
patent: WO 00/50639 (2000-08-01), None
patent: WO 02/18541 (2002-03-01), None
patent: WO 02/052044 (2002-07-01), None
patent: WO 02/066684 (2002-08-01), None
patent: WO 02/073196 (2002-09-01), None
patent: WO 02/073206 (2002-09-01), None
patent: WO 03/042654 (2003-05-01), None
patent: WO 2004/005882 (2004-01-01), None
patent: WO 2004/033722 (2004-04-01), None
patent: WO 2005/020784 (2005-03-01), None
patent: WO 2005/030947 (2005-04-01), None
patent: WO 2006/072075 (2006-07-01), None
patent: WO 2009/008896 (2009-01-01), None
patent: WO 2009/082743 (2009-07-01), None
patent: WO 2009/089120 (2009-07-01), None
patent: WO 2009/092032 (2009-07-01), None
patent: WO 2010/036353 (2010-04-01), None
patent: WO 2010/036943 (2010-04-01), None
patent: WO 2010/036969 (2010-04-01), None
patent: WO 2010/067372 (2010-06-01), None
Bishop et al., “Association between the polymorphicGRM3gene and negative symptom improvement during olanzapine treatment,”Schizophrenia Research, 77:253-260, 2005.
Brennan and Condra, “Transmission disequilibrium suggests a role for the sulfotransferase-4A1 gene in schizophrenia,”American Journal of Medical Genetics Part B(Neuropsychiatric Genetics), 139B:69-72, 2005.
Condra et al., “Evidence for two schizophrenia susceptibility genes on chromosome 22q13,”Psychiatric Genetics, 17(5):292-298, 2007.
Coughtrie, “Sulfation through the looking glass—recent advances in sulfotransferase research for the curious,”The Pharmacogenomics Journal, 2:297-308, 2002.
Gamage et al., “Human sulfotransferases and their role in chemical metabolism,”Toxicological Sciences, 90(1):5-22, 2006.
Hildebrandt et al., “Genetic diversity and function in the human cytosolic sulfotransferases,”The Pharmacogenomics Journal, 7:133-143, 2007.
Kauffman, “Sulfonation in pharmacology and toxicology,”Drug Metab. Rev., 36(3-4):823-843, 2004.
Lewis and Minchin, “Lack of exonic sulfotransferase 4A1 mutations in controls and schizophrenia cases,”Psychiatr. Genet., 19(1):53-55, 2009.
Lindsay et al., “Structure, function and polymorphism of human cytosolic sulfotransferases,”Curr. Drug Metab., 9(2):99-105, 2008.
McClay et al., “Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics,”Molecular Psychiatry, 1-10 (E-pub ahead of print), 2009.
Meltzer et al., “Association ofSult4A1SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder,”Schizophrenia Research, 106:258-264, 2008.
Minchin et al., “Sulfotransferase 4A1,”Int. J. Biochem. Cell Biol., 40(12):2686-2691, 2008.
Schwonbeck et al., “Cohort analysis of a single nucleotide polymorphism on DNA chips,”Biosensors and Bioelectronics, 20:956-966, 2004.
Single Nucleotide Polymorphism Cluster Report: rs2285162, National Center for Biotechnology Information (NCBI), printed Oct. 19, 2009.
Single Nucleotide Polymorphism Cluster Report: rs2285166, National Center for Biotechnology Information (NCBI), printed Oct. 19, 2009.
Single Nucleotide Polymorphism Cluster Report: rs2285167, National Center for Biotechnology Information (NCBI), printed Oct. 19, 2009.
Single Nucleotide Polymorphism Cluster Report: rs763120, National Center for Biotechnology Information (NCBI), printed Nov. 2, 2009.
U.S. Appl. No. 12/612,438, entitled “Methods and Compositions for the Treatment of Psychotic Disorders Through the Identification of the Sult4A1-1 Haplotype,” by Timothy L. Ramsey and Mark D. Brennan, filed Nov. 4, 2009.
U.S. Appl. No. 12/646,723, entitled “Methods and Compositions for the Treatment of Psychotic Disorders Through the Identification of the SULT4A1-1 Haplotype,” by Timothy L. Ramsey and Mark D. Brennan, filed Dec. 23, 2009.
Wall and Pritchard, “Haplotype blocks and linkage disequilibrium in the human genome,”Nat. Rev. Genet., 4(8):587-597, 2003.
U.S. Appl. No. 12/858,917, entitled “Methods and Compositions for the Treatment of Psychotic Disorders Through the Identification of the SULT4A1-1 Haplotype,” by Timothy L. Ramsey and Mark D. Brennan, filed Aug. 18, 2010.
U.S. Appl. No. 12/939,049, entitled “Methods and Compositions for the Treatment of Psychotic Disorders Through the Identification of theSULT4A1-1Haplotype,” by Timothy L. Ramsey and Mark D. Brennan, filed Nov. 3, 2010.
International Search Report issued in PCT/US2010/055457 dated Feb. 17, 2011.
Brennan Mark D.
Ramsey Timothy L.
Bausch Sarae
Fulbright & Jaworski L.L.P.
Suregene, LLC
LandOfFree
Methods and compositions for the treatment of psychotic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of psychotic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of psychotic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683460